Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) from a strong sell rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

A number of other research analysts have also commented on the company. Stifel Nicolaus assumed coverage on Eupraxia Pharmaceuticals in a report on Thursday, May 21st. They issued a “buy” rating and a $25.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Oppenheimer began coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Eupraxia Pharmaceuticals Trading Up 5.0%

Shares of NASDAQ:EPRX opened at $8.42 on Friday. Eupraxia Pharmaceuticals has a 12-month low of $5.16 and a 12-month high of $9.32. The business has a 50 day moving average of $6.84 and a 200-day moving average of $6.99. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02. The stock has a market cap of $547.47 million, a PE ratio of -8.25 and a beta of 1.07.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. As a group, equities research analysts forecast that Eupraxia Pharmaceuticals will post -0.85 earnings per share for the current year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Affinity Asset Advisors LLC lifted its position in shares of Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock valued at $11,504,000 after acquiring an additional 1,289,005 shares during the period. Vivo Capital LLC bought a new position in shares of Eupraxia Pharmaceuticals in the third quarter worth $7,965,000. Jupiter Topco LLC acquired a new position in Eupraxia Pharmaceuticals in the second quarter valued at about $6,851,000. Seven Fleet Capital Management LP acquired a new position in Eupraxia Pharmaceuticals in the first quarter valued at about $5,137,000. Finally, Redmile Group LLC bought a new stake in Eupraxia Pharmaceuticals during the first quarter worth about $5,068,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.